Background {#Sec1}
==========

Glaucoma is a group of optic neuropathies characterized by the degeneration of the optic nerve and loss of retinal ganglion cells (RGCs) \[[@CR1]--[@CR3]\]. Among the mechanisms that have been correlated with glaucomatous neurodegeneration is the activation of the retinal innate immune response \[[@CR4]--[@CR6]\], which has been replicated in animal models of glaucoma and following optic nerve trauma \[[@CR7]--[@CR11]\]. Since the eye is immune privileged and protected from invading peripheral immune cells \[[@CR12]\], it relies on the adaptation of the retinal glial cells to incorporate innate immune functions in response to injury. In the retina, there are three types of glial cells that maintain health and function. Microglia are found in the plexiform layers where neurons form synapses \[[@CR8]\], and astrocytes contact the unmyelinated axons of RGCs as they pass over the retina in the nerve fiber layer \[[@CR13]\]. The third type is the Müller glia, which are the most abundant glial population in the eye \[[@CR14]--[@CR16]\]. Müller glia span the full thickness of the retina and form connections with every cell type involved in processing light signals \[[@CR14], [@CR17]\].

The retinal glia undergo distinct morphological and behavioral changes to enter an activated state in response to injuries such as optic nerve crush, optic nerve transection, and in animal models of glaucoma \[[@CR8], [@CR13], [@CR18]--[@CR20]\]. Microglia become "amoeboid" and exhibit proliferative potential, retracted processes with enlarged somas \[[@CR13], [@CR21]\], and they upregulate factors including allograft inflammatory factor 1 (*Aif1/Iba1*) and *Cd68* \[[@CR22], [@CR23]\]. Müller cells and astrocytes, while non-proliferative, upregulate glial fibrillary acidic protein (*Gfap*) and nestin (*Nes*) \[[@CR24]--[@CR27]\], and become hypertrophic \[[@CR28]\]. Activated glia have been shown to phagocytose cellular debris, generate cytokines, and present antigens \[[@CR29]--[@CR34]\].

Despite the well-documented activation response of the retinal glia following axonal injury, the consequence of this activation response on RGC survival continues to be debated. One model has been that of "secondary degeneration", which predicts that RGC neurodegeneration occurs in two waves. First, axonal injury causes intrinsic apoptosis in a subset of critically damaged RGCs, after which a second wave of extrinsic apoptotic death is triggered by inflammatory molecules produced by activated retinal glia. The phenomenon of secondary degeneration was initially developed following a series of studies utilizing partial optic nerve crush, or partial optic nerve axotomy. In this damage paradigm, RGCs with presumably intact axons also exhibit degeneration \[[@CR9], [@CR35]--[@CR41]\]. The supposition that activated glial cells mediate the process of secondary degeneration was supported by improved RGC survival after acute optic nerve injury when glial activation was attenuated by the anti-inflammatory action of minocycline \[[@CR42], [@CR43]\], and when the signaling potential of tumor necrosis factor alpha (TNFα) through TNFα receptor 1 (TNFR1) was blocked \[[@CR44]\]. In chronic optic nerve damage conditions, such as glaucoma, the phenomenon of secondary degeneration is less apparent; however, RGC survival in experimental glaucoma was also improved by treatment with minocycline \[[@CR20], [@CR43], [@CR45]\] and with the TNFα decoy receptor, Etanercept \[[@CR46]\], or in mice lacking the *Tnf* gene \[[@CR47]\].

Additionally, in studies evaluating changes of the retinal transcriptome in both acute and chronic models of optic nerve damage, the involvement of neuroinflammatory pathways are almost universally identified \[[@CR48], [@CR49]\]. Interestingly, RGC death following optic nerve injury and cytokine-mediated damage occurs by distinct mechanisms: the former occurs through intrinsic apoptosis and is mediated by BAX \[[@CR50], [@CR51]\], while the latter occurs through extrinsic apoptotic pathways that are predicted to be BAX independent. Paradoxically, RGC death is completely abrogated in *Bax*^−/−^ mice after both acute and chronic optic nerve damage \[[@CR50]--[@CR54]\], a pattern that would be inconsistent with secondary activation of degeneration mediated through cytokine activation of extrinsic apoptosis. This might suggest that *Bax*^−/−^ mice are resistant to cytokine-mediated damage; however, like wild types, *Bax*^−/−^ mice retain susceptibility to TNFα \[[@CR55]\], indicating that the extrinsic apoptotic pathways remain functional. It is therefore possible that the glial cells in *Bax*^−/−^ mice exhibit an altered activation state in which the damaging cytokines that initiate extrinsic apoptosis are not produced. To further examine this phenomenon in the *Bax*^−/−^ mice, we explored the mechanisms of glial activation using the mouse model of optic nerve crush (ONC).

In this model, the site of damage in the optic nerve is "distant" from the retina, suggesting a secondary signal within the retina is required to activate the resident glia. In the context of secondary degeneration, the likely source of activating signals is the RGC somas that are lost during the primary wave of degeneration. A variety of signaling molecules have been attributed to dying neurons, including (but not limited to) cytokines, reactive oxygen species, damage-associated molecular patterns (DAMPs), excessive neurotransmitters, and heat shock proteins \[[@CR56]--[@CR59]\]. An attractive candidate in the retina, however, is ATP. There is growing evidence that this nucleotide is released by dying neurons and signals extracellularly as a danger signal \[[@CR60]--[@CR62]\]. Although not studied in models of acute optic nerve damage, there is evidence that cells affected in more moderate models of intraocular pressure-mediated stress exhibit purinergic signaling responses. Elevated levels of ATP have been found in the aqueous humor of glaucoma patients \[[@CR63]\], the vitreal compartment of bovine retinal eye cups subjected to increased hydrostatic pressure \[[@CR64]\], and following pressure-induced mechanical deformation of neuronal cultures \[[@CR65]\]. The release of ATP can also be blocked with probenecid, carbenoxolone, and ^10^panx, implicating a role for pannexin 1 (PANX1) hemichannels in mediating ATP release \[[@CR65]--[@CR67]\].

Once ATP reaches the extracellular space, this nucleotide can signal through two families of receptors, called P1 and P2. While P1 receptors are only activated by adenosine, P2 receptors respond to extracellular nucleotides including ATP \[[@CR68]\]. P2 receptors are further categorized as metabotropic G-protein-coupled P2Y receptors and ionotropic P2X receptors \[[@CR69]\]. A number of the P2X receptor subunits are expressed in the retina \[[@CR68]--[@CR70]\], but a considerable amount of research has been conducted on the P2X7 receptor (P2X7R). Stimulating P2X7R has been linked to the activation of both microglia and macroglia \[[@CR71], [@CR72]\], as well as the production of inflammatory cytokines \[[@CR73]\], while inhibiting the receptor has reduced macrophage recruitment and cytokine production at the site of optic nerve crush in rats \[[@CR74]\]. The activation of P2X7R in vitro and in vivo has also been shown to damage RGCs, although the glial contribution to RGC damage was not examined in vivo, leaving open the possibility that glial activation (initiated by ATP) causes secondary degeneration of RGCs \[[@CR75]--[@CR77]\].

In this study, we examined how blocking RGC death in the crush model altered the activation state of microglia and macroglia, as a function of activation markers at the mRNA and protein levels. We found that glial activation was attenuated when cell death was blocked in *Bax*^−/−^ mice. Additionally, an ATP agonist elicited macroglial activation without optic nerve trauma, while an ATP antagonist for purinergic receptors attenuated the activation response after crush.

Methods {#Sec2}
=======

Animals {#Sec3}
-------

Adult mice (Jackson Laboratory, Bar Harbor, ME) were handled in accordance with the Association for Research in Vision and Ophthalmology statement on the use of animals in research. All experimental protocols and the ethical care of the mice were reviewed and approved by the Institutional Animal Care and Use Committee of the University of Wisconsin. Mice were housed in microisolator cages and kept on a 12-h light/dark cycle and maintained on a 4 % fat diet (8604 M/R; Harland Teklad, Madison, WI). *Bax-*deficient mice were generated from breeding *Bax*^*+/−*^ animals on a C57BL/6J background. Mice harboring LoxP sites flanking exons 3 and 4 in the *Panx1* gene (*Panx1*^*fl/fl*^), as previously described \[[@CR78]\], were used to generate *Panx1* total knockout mice and RGC conditional knockouts. For complete knockout mice, *Panx1*^*fl/fl*^ animals were crossed with transgenic mice carrying CRE recombinase under the control of the CMV immediate early promoter. For RGC-selective deletion of *Panx1*, *Panx1*^*fl/fl*^ mice received an intraocular injection of a replication-deficient AAV2 virus carrying a CRE expression cassette (AAV2-Cre/GFP, Vector Biolabs, Philadelphia, PA and University of North Carolina Viral Vector Core, Chapel Hill, NC), which transduces approximately 85 % of the RGCs with only minimal transduction of some Müller cells \[[@CR79], [@CR80]\]. All genotypes were on the C57BL/6 background.

Optic nerve crush surgery and intraocular injections {#Sec4}
----------------------------------------------------

ONC was performed as previously described \[[@CR55], [@CR81]\]. Briefly, mice were anesthetized with ketamine (120 mg/kg) and xylazine (11.3 mg/kg), and the eye was numbed with a drop of 0.5 % proparacaine hydrochloride (Akorn, Lake Forest, IL). A lateral canthotomy was performed followed by an incision through the conjunctiva at the limbal junction, and the optic nerve was exposed and clamped for 3 s using self-closing N7 forceps (Fine Science Tools, Foster City, CA). After surgery, the eye was covered with triple antibiotic ointment, and a subcutaneous injection of Buprenex (0.2 mg/kg) was delivered to alleviate pain. The right eye was left as an untreated control for each experiment.

Intraocular injections were performed as previously described \[[@CR55], [@CR81]\]. Briefly, mice were anesthetized with ketamine/xylazine, and a drop of proparacaine was applied to numb the eye. A small hole was made through the conjunctiva and scleral tissue with a 30G needle, and then a 35G beveled Nanofil needle attached to a Nanofil syringe (World Precision Instruments, Inc, Sarasota, FL) was inserted through the hole and a 1-μl volume of PBS, 40 mM *N*-*methyl*-[d]{.smallcaps}-asparate (NMDA), 250 μM 2′(3′)-O-(4-benzoyl)benzoyl adenosine 5′-triphosphate triethylammonium salt (BzATP; Sigma, St. Louis, MO), 250 μM oxidized ATP (oxATP; Sigma), or AAV2-Cre/GFP was slowly delivered into the vitreous over 30 s. Care was taken not to damage the lens. After delivery, the needle was held in the eye for an additional 30 s before being retracted. After surgery, the eye was covered with triple antibiotic ointment, a subcutaneous injection of Buprenex was delivered to alleviate pain, and the mouse was allowed to recover. The virus was diluted 1:10 in PBS containing 5 % glycerol prior to injection, and mice were housed for a minimum of 4 weeks after gene delivery to allow for expression of the transgene.

RNA isolation and quantitative analysis of mRNA expression by quantitative PCR {#Sec5}
------------------------------------------------------------------------------

RNA isolations were performed as previously described \[[@CR55]\]. Briefly, mice were euthanized with a lethal overdose of pentobarbital sodium, and retinal tissue was collected and flash frozen on dry ice. Total RNA was isolated from a minimum of three pooled retinas, and 4 μg were treated with DNase I (Promega, Madison, WI), purified by phenol/chloroform extraction, and converted to (complementary DNA) cDNA with oligo(dT) 15 primers and Moloney murine leukemia virus (M-MLV) reverse transcriptase (Promega). The cDNA samples were then diluted and an equivalent amount of 2 ng of mRNA was analyzed by quantitative PCR (QPCR) for changes in gene expression of *Aif1*, *Cd68*, *Gfap, Nes*, *Nrn1*, *Panx1*, and *Sncg. S16* ribosomal protein mRNA was used as a reference gene. The primer sequences are listed in Table [1](#Tab1){ref-type="table"}, and the identity of all products was confirmed by sequence analysis. The cDNA was added to diluted SYBR Green PCR master mix (Applied Biosystems, Grand Island, NY) with 0.25 μM of each primer in a 20 μl reaction volume. Cycling conditions were 95 °C (15 s) and 60 °C (60 s) for 40 cycles with a dissociation step. Each cDNA sample was run in triplicate on an ABI 7300 Real-Time PCR system (Applied Biosystems), and absolute transcript abundance was determined using a standard curve of the target molecule run on the same array. Data from different samples were normalized to *S16*.Table 1Quantitative PCR primer sequencesGene NamePrimer sequence 5′ ➔ 3′Size (bp)*Aif1*F: AGAGAGGTGTCCAGTGGC\
R: CCCCACCGTGTGACCTCC200*Cd68*F: GGACTACATGGCGGTGGAAT\
R: GCAAGAGAAACATGGCCCGA229*Gfap*F: CAAACTGGCTGATGTCTACC\
R: AGAACTGGATCTCCTCATCC269*Nes*F: GGGCCAGCACTCTTAGCTTTGATA\
R: TGAGCCTTCAGGGTGATCCAG106*Nrn1*F: TTCACTGATCCTCGCGGTGC\
R: TACTTTCGCCCCTTCCTGGC238*Panx1*F: GCTGCACAAGTTCTTCCCCT\
R: ATCTCGAGCACTCTTGGCAG175*Sncg*F: GACCAAGCAGGGAGTAACGG\
R: TCCAAGTCCTCCTTGCGCAC240*S16*F: CACTGCAAACGGGGAAATGG\
R: TGAGATGGACTGTCGGATGG198

Immunofluorescence and microscopy {#Sec6}
---------------------------------

Immunofluorescence was performed on 10-μm thick frozen sections as previously described \[[@CR55]\]. Slides were rinsed in PBS and then blocked in 0.1 % Triton-X and 2 % BSA in PBS for 1 h at room temperature. Primary antibodies for GFAP (Dako, Cat\# Z0334) or AIF1 (Wako, Cat\# 019-19741) were incubated at 1:1000 either overnight (GFAP) or for 3 days (AIF1). After washing with PBS, secondary antibodies conjugated to Texas Red or FITC (Jackson ImmunoResearch Inc., West Grove, PA) were diluted 1:1000 and incubated in the dark for 2 h at room temperature. Slides were thoroughly rinsed in PBS before being incubated with 300 ng/ml DAPI for 5 min at room temperature. Finally, the slides were rinsed in PBS and coverslipped with Immu-Mount (Fisher Scientific, Waltham, MA) and stored at 4 °C in the dark. Whole mounts labeled with AIF1 were processed in the same manner, with the exception that retinas were mounted on Superfrost Plus Slides (Fisher Scientific) prior to staining. Images were taken at ×200 and ×400 magnification from the mid-peripheral retina. Microglial counts were obtained from at least six fields per retina of approximately 0.04 mm^2^ in size. For Sholl analyses of retinal microglia in the ganglion cell layer, a grid of concentric circles of 20, 40, 60, and 80 μm in diameter was laid over the cell nucleus of AIF1-staining cells in images from retinal whole mounts and the numbers of intersections of processes was counted. A minimum of 50 cells was measured for each condition. Sizes of microglia in non-damaged retinas of both genotypes of mice were measured from images using ImageJ (v1.45s), while the cells were scored as either amoeboid-like or ramified-like. A minimum of 106 cells were measured and scored for each genotype. All immunofluorescent photographs were acquired using a Zeiss Axioplan 2 Imaging microscope (Carl Zeiss Microimaging, Inc., Thornwood, NY) with a digital black and white camera. Images were analyzed using the Zeiss Axiovision Image Analysis software v4.6 (Carl Zeiss Microimaging, Inc.).

Statistical analyses {#Sec7}
--------------------

Means from QPCR quantification are reported with the standard deviation of the mean. Microglial counts and Sholl analyses are reported with standard error of the mean. Statistical significance between two means was determined using a two-sided Student's *t* test, ANOVA was used to compare means from multiple samples, and a chi-squared test was used to evaluate the distribution of microglial morphology in control retinas. *P* values were considered significant at a value equal to or less than 0.05.

Results {#Sec8}
=======

Microglial activation is attenuated in *Bax*^−/−^ mice after crush {#Sec9}
------------------------------------------------------------------

The central hypothesis of secondary degeneration is that activation of the retinal neuroinflammatory response requires an initial wave of RGC somatic degeneration principally affected by axonal damage in the optic nerve. To test this hypothesis, we used *Bax*-deficient mice, which exhibit complete resistance to RGC soma death in an acute optic nerve crush paradigm. We first evaluated the *Bax*^−/−^ mice for expression of the microglial activation marker, *Aif1*, and the microglial/macrophage marker *Cd68* \[[@CR23]\]. By 7 days post-injury, *Aif1* expression in wild-type mice was dramatically elevated in the crushed eye over the contralateral eye, while *Bax*-deficient mice only showed a modest increase in *Aif1* expression (Fig. [1a](#Fig1){ref-type="fig"}, *P* \< 0.0001 for *Bax*^−/−^ mice compared to wild types). By 14 days, *Aif1* expression declined in wild-type mice but remained significantly higher than the mRNA levels in *Bax*-deficient retinas, and at 21 days, microglial activation trended towards baseline levels in both genotypes and was no longer statistically significant. The expression of *Cd68* followed a similar trend as *Aif1*, with levels rising at 7 days post-crush to a significantly higher level in the wild-type mice relative to the *Bax*^−/−^ mice (Fig. [1b](#Fig1){ref-type="fig"}, *P* \< 0.005). By 14 days, expression began to decline in the crushed eye of both genotypes, although mRNA levels remained significantly higher in the injured retinas of wild-type mice. At 21 days, *Cd68* expression in the knockout mice was slightly higher than the wild types, although the mRNA abundance was relatively low in both genotypes.Fig. 1Expression of *Aif1* and *Cd68* are attenuated in *Bax*-deficient mice after optic nerve crush. Wild-type and *Bax* ^−/−^ mice were subjected to crush injury and evaluated for microglial activation markers. **a** In wild-type mice, the mRNA expression of *Aif1* peaked by 7 days post-injury, and then declined at 14 days and again at 21 days. In the *Bax* ^−/−^ mice, *Aif1* expression was significantly attenuated relative to wild-type mice at 7 and 14 days. By 21 days, the levels of *Aif1* appeared to be returning to baseline in both genotypes, and were no longer significantly different (*P* = 0.07). **b** The change in *Cd68* expression followed a similar trend as *Aif1*, with levels peaking in the wild-type mice at 7 days before declining at 14 and again at 21 days. The *Bax* ^−/−^ mice, however, exhibited a significant attenuation in *Cd68* expression at 7 and 14 days post-crush. By 21 days, expression in the knockout mice was significantly elevated over the wild types; however, expression in both genotypes remained low. Data is presented as mean ± SD. \**P* \< 0.005. For each genotype at each time point, *n* ≥ 3

The QPCR data was supported by immunolabeling in retinas for AIF1 protein after optic nerve crush (Fig. [2](#Fig2){ref-type="fig"}). In wild-type mice (Fig. [2a](#Fig2){ref-type="fig"}--[d](#Fig2){ref-type="fig"}), AIF1 positive cells were sparsely detected in the uncrushed contralateral eye, and the microglia present were small with branched processes, characteristic of resting "ramified" microglia \[[@CR21], [@CR29]\]. At 7 and 14 days, a population of AIF1-positive cells was abundant in the ganglion cell layer (GCL) and the associated nerve fiber layer (NFL), inner nuclear layer (INL), and outer nuclear layer (ONL). By 21 days after injury, AIF1 labeling decreased throughout the retina in wild-type mice, but still exhibited more labeling than the contralateral eye. The *Bax*^−/−^ mice showed a similar baseline expression of AIF1 in the retina; however, after crush, the level of AIF1 labeling was markedly reduced at 7, 14, and 21 days relative to the wild-type mice (Fig. [2e](#Fig2){ref-type="fig"}--[h](#Fig2){ref-type="fig"}). The morphology of AIF1-expressing cells in the NFL was also examined in whole-mounted retina preparations (Fig. [3](#Fig3){ref-type="fig"}). In wild-type mice at 7 days after injury, the numbers of cells appeared to increase and then decrease by 14 and 21 days (Fig. [3b](#Fig3){ref-type="fig"}--[d](#Fig3){ref-type="fig"}). Crush injury did not appear to alter the density of the microglia in *Bax*^−/−^ mice (Fig. [3e](#Fig3){ref-type="fig"}--[h](#Fig3){ref-type="fig"}). Quantification of cell density indicated that by 7 days post-crush, wild-type retinas showed a significant increase in the density of microglial cells in the NFL of crushed retinas (*P* \< 0.0001 relative to contralateral eyes), which persisted through 14 days after injury (Fig. [4a](#Fig4){ref-type="fig"}). The density of AIF1-positive microglia peaked at 7--14 days post-crush, consistent with the peak in mRNA expression at 7 days (Fig. [1](#Fig1){ref-type="fig"}) and other studies \[[@CR11]\]. By 21 days, the density of microglia was still significantly higher than the contralateral eye, but the numbers were declining. Unlike wild-type mice, *Bax*-deficient mice exhibited only a modest increase in microglial density, although the density of microglia gradually rose in both the injured and contralateral retinas of the knockout mice. Importantly, *Bax*^−/−^ mice exhibited a significantly lower density of microglia, relative to injured retinas of wild-type mice, at both 7 and 14 days post-crush (*P* \< 0.0001). Interestingly, control retinas of both *Bax*^+/+^ and *Bax*^−/−^ mice showed a modest increase in microglial density over the time course examined, indicative of a contralateral eye effect from optic nerve injury, which has been described by others \[[@CR82], [@CR83]\].Fig. 2Upregulation of AIF1 is attenuated in *Bax*-deficient mice after optic nerve crush. Cross sections of eye cups were analyzed for changes in AIF1 expression after crush injury. **a**--**d** Although a baseline level of AIF1-positive cells (*red label*) populated the retina in control eyes, following optic nerve crush *Bax* ^+/+^ retinas exhibited an increase in the number of AIF1-positive cells. Microglial cells appeared in the inner plexiform layer (IPL), outer plexiform layer (IPL), and ganglion cell layer (GCL). **e**--**h** In *Bax* ^−/−^ mice, the amount of AIF1 labeling was significantly attenuated after crush, and the intensity of AIF1 labeling did not appear to change. Inner nuclear layer (INL), outer nuclear layer (ONL). DAPI nuclear counterstain (*blue label*). *Scale bar* 50 μm. For each genotype at each time point, *n* ≥ 3Fig. 3Immunofluorescent images of whole-mounted retinas stained for AIF1. Representative nerve fiber layer images of retinas from wild-type and *Bax* ^−/−^ mice stained for AIF1 (*red label*) at 7, 14, and 21 days post-crush. These are representative of the images used to quantify the number of microglia present after crush. **a**--**d** In wild-type mice, a baseline resting microglial population was present in the retina. These microglia exhibited small somas with numerous long processes. After crush, the number of microglia increased, and the morphology transitioned to an amoeboid state as the cell somas thickened and the processes retracted. By 21 days, while there was still a prominent population of AIF1-positive microglia, the number of cells was beginning to decline. **e**--**h** The number and morphology of microglia in the *Bax* ^−/−^ mice contrasted starkly with the population in the wild types. The number of microglia in the knockout mice did not increase by 7 days after crush, and after a modest increase in AIF1 labeling at 14 days, the number of microglia dropped considerably. Interestingly, the morphology of microglia in the *Bax* ^−/−^ mice appeared amoeboid, even in the control eyes, characteristic of an early activation state. These microglia exhibited very few processes and thickened somas. Microglial counts were obtained from at least six images, and each image is approximately 0.04 mm^2^. DAPI nuclear counterstain (*blue label*). *Scale bar* 50 μm. For each genotype at each time point, *n* ≥ 3Fig. 4Microglial changes in the peripheral retinal nerve fiber layer of *Bax* ^−/−^ mice after crush. **a** The number of AIF1-positive cells were quantified from retinal whole mounts of wild-type and *Bax* ^−/−^ mice after crush. Consistent with past literature, the number of microglia in the wild-type retinas rose dramatically by 7 days after crush, and remained significantly elevated at 14 days before declining at 21 days. Microglial counts in the *Bax* ^−/−^ mice were significantly attenuated relative to the wild types, and although a modest increase was quantified in both the experimental and control eyes (suggesting a contralateral effect from crush injury), the number of microglia in the crushed retinas of *Bax* ^−/−^ mice was significantly attenuated at 7 and 14 days post-crush. By 21 days, the microglial counts were no longer statistically significant between the two genotypes. Data is presented as mean ± SE. \**P* \< 0.0001. For each genotype at each time point, *n* ≥ 3. **b** Sholl analysis of microglial morphology showing the numbers of processes crossing the 40-μm grid line (complete data shown in Additional file [1](#MOESM1){ref-type="media"}: Figure S1) for AIF1-positive cells in both crushed and contralateral control retinas of each genotype. Wild-type microglia exhibited an increase in processes at 7 days after crush (\**P* \< 0.0001 relative to contralateral wild-type retinas), while microglia in Bax-deficient mice exhibited a significant decrease in processes by 14 days (\*\**P* \< 0.0001, relative to control retinas). By 21 days, both control and crush retinas of each genotype exhibited similar levels of ramification, which were significantly reduced compared to earlier time points (*P* \< 0.005). Data is presented as mean ± SE. A minimum of 50 cells from at least three mice, at each time point, were measured

A Sholl analysis was also conducted to quantify morphological changes in these cells after optic nerve damage. Quantification of retinas in each genotype, at different days, is shown in Additional file [1](#MOESM1){ref-type="media"}: Figure S1A--F. Figure [4b](#Fig4){ref-type="fig"} shows data for all genotypes at all days for processes crossing the 40-μm grid line. Cells in wild-type retinas show a significant increase in processes 7 days after optic nerve damage (compared to contralateral eyes, *P* \< 0.001), while at 14 and 21 days, cells in both retinas had similar morphology, which was overall reduced in complexity relative to their shape at 7 days (*P* \< 0.0005). Cells in *Bax*^−/−^ retinas showed no change between eyes at 7 days after crush, but had significantly fewer processes in the damaged eyes by 14 days (*P* \< 0.001). As with the wild-type retinas, there was an overall reduction in the numbers of processes in both eyes at 14 and 21 days, compared to 7 days (*P* \< 0.005).

Morphologically, the microglia in the uncrushed retinas appeared different between the two genotypes. Wild-type mice exhibited a range of morphologies for microglia varying from cells with thick cell bodies and large processes to cells with small somas and highly ramified fine processes. While a similar distribution was also evident in the *Bax*^−/−^ mice, a greater proportion of cells appeared to have thick cell bodies and large processes. The average numbers of processes as assessed by the Sholl analysis (see Fig. [4b](#Fig4){ref-type="fig"}), and the average area of cells between the two genotypes, were not significantly different (*P* = 0.71 and 0.32, respectively). However, scoring of images for amoeboid-like or ramified-like morphologies showed that wild-type mice presented with \~58 % ramified-like microglia, while *Bax*^−/−^ animals presented with \~60 % amoeboid-like cells, which was significantly different (*P* = 0.003).

The microglial response in the optic nerve head of the *Bax*^+/+^ and *Bax*^−/−^ mice was also noticeably different. In control eyes, similar levels of AIF1-positive cells populated the ONH of both genotypes (Fig. [5a, d](#Fig5){ref-type="fig"}). In the wild-type mice, crush injury caused the number of microglia and intensity of AIF1 staining to increase at 7 and 14 days (Fig. [5b, c](#Fig5){ref-type="fig"}). In contrast, in the *Bax*^−/−^ mice the amount of AIF1 labeling was quite attenuated despite an increase in the number of microglia in the injured relative to the control optic nerve head, compared to wild-type mice (Fig. [5e, f](#Fig5){ref-type="fig"}).Fig. 5Microglial activation is present but reduced in the optic nerve head of *Bax* ^−/−^ mice after crush. The microglial populations in the optic nerve heads of *Bax* ^+/+^ and *Bax* ^−/−^ mice were also compared. **a**--**c** Wild-type mice exhibited a clear increase in the intensity and number of AIF1-expressing cells (*red label*) at both 7 and 14 days after crush. **d**--**f** Unlike in the retina, mice deficient for *Bax* also exhibited an increase in microglia at the optic nerve head 7 and 14 days post-crush, although the number of cells and intensity did not appear as high as the wild-type counterparts. DAPI nuclear counterstain (*blue label*). *Scale bar* 50 μm. For each genotype at each time point, *n* ≥ 3

Macroglial activation is attenuated in *Bax*^−/−^ mice after optic nerve crush {#Sec10}
------------------------------------------------------------------------------

Mice deficient for *Bax* also exhibited a reduction in the expression of macroglial activation markers after optic nerve crush. As shown in Fig. [6a](#Fig6){ref-type="fig"}, at 7 days after crush, *Gfap* expression in the wild types was significantly elevated above the contralateral eye (*P* \< 0.0001), while the injured retinas of *Bax*^−/−^ mice showed only a modest increase that was greatly attenuated compared to wild-type mice (*P* \< 0.0001). By 14 days, macroglial activation increased in both genotypes, however expression in the wild type mice still remained significantly elevated over *Bax*^−/−^ mice (*P* \< 0.0001). By 21 days, *Gfap* expression began to trend towards baseline levels in both genotypes, and no longer retained statistical significance (*P* = 0.28). A second macroglial activation marker, Nestin (*Nes)* \[[@CR24], [@CR26], [@CR27], [@CR84]\], was also analyzed by QPCR. Similar to *Gfap*, the expression of *Nes* at 7 and 14 days post-crush was attenuated in the crushed retinas of *Bax*^−/−^ mice relative to the levels observed in the crushed wild-type retinas (Fig. [6b](#Fig6){ref-type="fig"}, *P* \< 0.001). By 21 days, expression continued to decline in the wild-type mice, but rose slightly in the *Bax*^−/−^ mice, although the expression levels were no longer statistically different between the two genotypes (*P* = 0.37).Fig. 6Expression of macroglial markers *Gfap* and *Nes* are significantly attenuated after crush in *Bax* ^−/−^ mice. Wild-type and *Bax* ^−/−^ mice were evaluated for macroglial activation markers following optic nerve crush. **a** In wild-type mice, *Gfap* mRNA expression rose sharply by 7 days, and peaked at 14 days before declining again at 21 days post-crush. The *Bax* ^−/−^ mice, however, showed no change in *Gfap* expression 7 days after crush, and although expression was elevated by 14 days, it still remained significantly lower than the wild-type mice. By 21 days, both genotypes were trending towards baseline and were no longer significantly different. **b** A second macroglial activation marker, *Nes*, was also elevated in wild-type mice by 7 days after crush, after which expression steadily declined at 14 and again 21 days. Although *Bax* ^−/−^ mice also exhibited a rise in *Nes* expression at 7 and 14 days post-crush, the values were significantly lower than those seen in wild-type mice. By 21 days *Nes* expression levels were no longer significant between the wild-type and knockout mice. Data is presented as mean ± SD. \**P* \< 0.001, \*\**P* \< 0.0001. For each genotype at each time point, *n* ≥ 3

Immunofluorescent labeling for GFAP performed on retinal sections showed that astrocytes expressed a baseline level of GFAP in the NFL of both *Bax*^+/+^ and *Bax*^−/−^ mice (Fig. [7a, e](#Fig7){ref-type="fig"}). At 7 days after crush, the GFAP labeling intensified in the wild-type mice and fibers appeared through the retinal layers indicative of Müller cell expression. This expression pattern of GFAP persisted in the wild-type mice at 14 and 21 days, although at the latter time point, GFAP expression was markedly reduced. The *Bax*^−/−^ retinas contrasted starkly with the wild-type mice at all time points analyzed (Fig. [7e--h](#Fig7){ref-type="fig"}). There was a complete absence of GFAP labeling in the Müller cells, resulting in a labeling pattern that did not appear to differ from the control eyes.Fig. 7Müller cell upregulation of GFAP is absent after crush in *Bax* ^−/−^ mice. The expression of GFAP protein (*green label*) was also evaluated in retinal sections from wild-type and *Bax* ^−/−^ mice after crush. **a**--**d** Astrocytes expressed a baseline level of GFAP in the retinas of wild-type mice, and by 7 days after crush, there was a dramatic increase in GFAP labeling in the ganglion cell layer (GCL), as well as through the retinal layers, indicative of Müller cell activation. Müller cells continued to express GFAP at 14 and 21 days, although expression levels appeared to decline at the latter time point. **e**--**h** While retinas of *Bax* ^−/−^ mice also expressed GFAP in the astrocytes of control eyes, after crush, there was no upregulation of GFAP in the GCL, or through the retinal layers. Inner nuclear layer (INL), outer nuclear layer (ONL). DAPI nuclear counterstain (*blue label*). *Scale bar* 50 μm. For each genotype at each time point, *n* ≥ 3

Microglial and macroglial activation are not dependent on BAX {#Sec11}
-------------------------------------------------------------

The attenuated glial response in *Bax*-deficient mice supports the hypothesis that RGC soma death is an important event in the signaling of retinal glial activation. To strengthen this interpretation, we next examined if retinal glia in *Bax*^−/−^ mice could become activated using an alternative damage paradigm. While BAX has not been linked to glial activation, we wanted to confirm that *Bax-*deficient glia were capable of upregulating *Aif1* and *Gfap*. In this experiment, we introduced the glutamate analog *N*-*methyl*-[d]{.smallcaps}-aspartate (NMDA) by an intravitreal injection, which has previously been shown to kill RGCs in both wild-type and *Bax*-deficient mice \[[@CR50]\]. NMDA has also been reported to directly interact with NMDA receptors expressed by Müller cells \[[@CR85]\]. Examination of both transcript levels and protein immunostaining showed a predictable microglial and macroglial response in both genotypes. By 7 days post-NMDA injection, *Aif1* and *Gfap* mRNA expression were significantly elevated in both genotypes of mice (Fig. [8a](#Fig8){ref-type="fig"}, *P* \< 0.0001 relative to contralateral eyes). Immunofluorescent labeling also revealed a clear increase in AIF1-positive cells in the GCL and plexiform layers of *Bax*^−/−^ retinas (Fig. [8b, c](#Fig8){ref-type="fig"}), as well as an increase in GFAP labeling in the GCL and through the retinal layers, indicating Müller cell activation (Fig. [8d, e](#Fig8){ref-type="fig"}). Wild-type mice exhibited similar changes in protein expression following NMDA treatment (data not shown).Fig. 8NMDA treatment triggers microglial and macroglial activation in *Bax* ^−/−^ mice. Wild-type and *Bax* ^−/−^ mice received an intraocular injection of NMDA to confirm that *Bax-*deficient glia were capable of mounting an activation response. Mice were evaluated for microglial and macroglial activation 7 days post-injection. **a** Both wild-type and *Bax* ^−/−^ mice exhibited a significant increase in the expression of *Aif1* and *Gfap* relative to control eyes. The values for *Aif1* expression were not statistically different between the two genotypes, although *Gfap* expression was significantly higher in *Bax* ^−/−^ mice relative to the wild-type mice (\**P* \< 0.05). **b**, **c** Immunofluorescence also revealed a clear increase in AIF1 labeling (*red*) in the retinas of *Bax* ^−/−^ mice, with microglia appearing in the ganglion cell layer (GCL) and inner and outer plexiform layers. **d**, **e** The expression of GFAP (*green label*) was also confirmed in *Bax* ^−/−^ mice. A clear increase in labeling was seen in the GCL, as well as through the retinal layers, indicating that *Bax* ^−/−^ Müller glia are capable of upregulating GFAP. **a** Data is presented as mean ± SD. Inner nuclear layer (INL), outer nuclear layer (ONL). DAPI nuclear counterstain (*blue label*). *Scale bar* 50 μm. For each genotype, *n* ≥ 3

ATP analogs trigger an increase in macroglial activation markers {#Sec12}
----------------------------------------------------------------

There is growing evidence that injured neurons release ATP as a distress signal into the extracellular space, so we next wanted to determine if ATP analogs triggered glial activation in the retina. An intraocular injection of BzATP, an agonist selective for P2X receptors was delivered to wild-type mice, and microglial and macroglial activation markers were analyzed 48 h later. RGC gene expression was also monitored as a sign of injury, as previous studies have shown that this agonist can trigger RGC degeneration \[[@CR75], [@CR76]\]. While BzATP had no effect on inducing *Aif1* expression in microglia (Fig. [9a](#Fig9){ref-type="fig"}), this agonist triggered macroglial activation as indicated by a clear rise in *Gfap* mRNA expression (Fig. [9b](#Fig9){ref-type="fig"}), and an increase in GFAP protein labeling, particularly in the Müller glia (Fig. [9c](#Fig9){ref-type="fig"}--[e](#Fig9){ref-type="fig"}). BzATP was also delivered to *Bax*^−/−^ mice to confirm the functionality of purinergic receptors in the absence of BAX. By 48 h, *Gfap* expression was significantly elevated in the injected eye of both wild-type and *Bax*^−/−^ mice, relative to the contralateral eye (Fig. [9f](#Fig9){ref-type="fig"}). To determine if P2X receptor activation affected the RGCs, and cause indirect macroglial activation, we evaluated if it resulted in a decrease in RGC-specific gene expression, which is a sensitive indicator of damage to these cells \[[@CR54], [@CR86]--[@CR88]\]. BzATP had no effect on mRNA levels of *Nrn1* or *Sncg* (Fig. [9e](#Fig9){ref-type="fig"}), suggesting that RGCs were not adversely affected by this agonist, within the 48-h time frame evaluated in this experiment. This observation, added to the lack of microglial activation, indicated that BzATP was acting principally on the macroglia.Fig. 9A P2X receptor agonist triggers macroglial activation without inducing RGC injury. **a** Microglial activation was evaluated by monitoring *Aif1* expression 48 h after an intraocular injection of BzATP. This treatment was not found to affect *Aif1* mRNA levels relative to PBS-treated retinas (*P* = 0.21). Additionally, when mice were pre-treated with an intraocular injection of oxATP, a P2X receptor antagonist, prior to optic nerve crush, by 7 days post-crush *Aif1* expression by the microglial population not statistically different from PBS-injected retinas (*P* = 0.20). Data is presented as mean ± SD. For each treatment group, *n* ≥ 3. **b** Wild-type mice were treated with an intraocular injection of the P2X receptor agonist, BzATP, which induced a clear increase in *Gfap* mRNA expression by 48 h. **c**--**e** Immunofluorescence of retinal sections confirmed that BzATP triggered an increase in GFAP expression (*green label*), most obviously in the Müller cell population. The PBS-treated eyes did not exhibit an increase in GFAP. DAPI nuclear counterstain (*blue label*). *Scale bar* 50 μm. **f** The change in *Gfap* expression after BzATP treatment was also evaluated in *Bax* ^−/−^ mice. By 48 h, *Gfap* expression was elevated in both wild-type and knockout mice, indicative of functional purinergic receptors on *Bax*-deficient glia. Importantly, markers of RGC injury (*Sncg* and *Nrn1*) did not decline, indicating glial activation occurred in the absence of RGC injury. Data is presented as mean ± SD. Ganglion cell layer (GCL). \**P* \< 0.005. For each treatment group and genotype, *n* ≥ 3

A P2X receptor antagonist limits, but does not prevent, macroglial cell activation after optic nerve crush {#Sec13}
----------------------------------------------------------------------------------------------------------

While the previous results show that purinergic signaling can mediate activation of retinal macroglia, they do not verify if this mechanism of signaling is active in the optic nerve crush paradigm of damage. To test this, we examined if a P2X receptor antagonist (oxATP) was able to block macroglial activation after crush. We delivered an intraocular injection of the drug 24 h prior to, or 3 days post-crush, and analyzed for glial activation 7 days after surgery when peak activation is known to occur. The expression of *Gfap* was significantly elevated in the crushed eye of all treatment groups (Fig. [10](#Fig10){ref-type="fig"}, *P* \< 0.0005, relative to the contralateral eye); however, both pre-treating and post-treating, mice with an intraocular injection of oxATP attenuated *Gfap* expression by about half (Fig. [10a, e](#Fig10){ref-type="fig"}). Immunostaining in retinal sections showed that neither pre- nor post-crush treatment with oxATP was able to completely block GFAP expression in Müller cells, while there was a marked decrease in apparent staining in the NFL (Fig. [10b](#Fig10){ref-type="fig"}--[d](#Fig10){ref-type="fig"} and [f](#Fig10){ref-type="fig"}--[h](#Fig10){ref-type="fig"}), suggesting that the 50 % decrease in *Gfap* expression may be attributable to astrocytes. Consistent with no effect of BzATP on activating *Aif1* expression in microglia, oxATP had no effect on suppressing Aif1 expression after optic nerve crush (Fig. [9a](#Fig9){ref-type="fig"}).Fig. 10Treatment with oxATP reduces *Gfap* mRNA expression after crush injury. To evaluate purinergic signaling in the crush paradigm, wild-type mice were treated with oxATP either prior to or after optic nerve crush, and evaluated for macroglial expression of *Gfap* 7 days after injury. **a** Treatment with oxATP 1 day prior to optic nerve crush reduced *Gfap* transcript levels by about 50 %, relative to the PBS-injected eyes. **b**--**d** Despite the decline in *Gfap* mRNA levels, the upregulation of GFAP protein by Müller cells was not inhibited with oxATP pre-treatment. **e** A post-treatment of oxATP delivered 3 days after crush also reduced *Gfap* expression by about 50 %. **f**--**h** The post-treatment was also ineffective at reducing Müller cell activation, as fibers of GFAP were still clearly present through the retinal layers, and did not appear dramatically different than the PBS-treated retinas. Interestingly, oxATP in both treatment groups appeared to reduce the intensity of GFAP expression in the nerve fiber layer, suggesting oxATP may selectively affect astrocyte expression of the filament protein in the crush paradigm. **a**, **e** Data is presented as mean ± SD. \**P* \< 0.001. *Scale bar* 50 μm. For each treatment group, *n* ≥ 3 for quantitative analysis by QPCR, *n* = 3 for immunofluorescent labeling

*Panx1* deficiency in RGCs does not prevent macroglial activation after crush {#Sec14}
-----------------------------------------------------------------------------

It appears that purinergic signaling may play a role in triggering *Gfap* upregulation after crush, although the source of extracellular ATP in response to optic nerve damage is not known. We hypothesized that ATP was released from RGCs undergoing apoptosis, and wanted next to explore the mechanism by which ATP release may occur. One possible mechanism of ATP release involves the PANX1 hemichannel, which is expressed across the retinal cell types and is highly enriched in RGCs \[[@CR89]\]. This mechanism is consistent with the attenuated glial response observed in *Bax*^−/−^ mice, since dying cells are known to release ATP through caspase 3/7-mediated activation of the PANX1 protein \[[@CR60], [@CR90]\]. Since BAX activation is required for activation of caspases, it is reasonable to predict that *Bax*-deficient RGCs would not be able to activate PANX1 and release ATP. To test for whether glial activation is dependent on *Panx1* after injury, the *Panx1* gene was selectively disabled in either RGCs or all cell types in *Panx1-LoxP* mice using cell type-specific expression of CRE recombinase (see the ["Methods"](#Sec2){ref-type="sec"} section).

The retinas were first evaluated for *Panx1* mRNA by QPCR, which showed a complete abrogation of *Panx1* expression in *Panx1*^−/−^ mice, while RGC *Panx*^−/−^ retinas showed about a 50 % reduction in mRNA expression (Fig. [11a](#Fig11){ref-type="fig"}). Conditional knockout and wild-type mice were then subjected to optic nerve crush and evaluated for changes in macroglial *Gfap* expression. Wild-type mice and *Panx1*^−*/*−^ mice followed similar trends in *Gfap* expression, with levels peaking at 7 days and then declining at 14 days and again at 21 days (Fig. [11b](#Fig11){ref-type="fig"}). The RGC *Panx1*^−*/*−^ mice, however, consistently exhibited higher and sustained *Gfap* expression after crush relative to wild-type and *Panx1*^−/−^ mice. While *Gfap e*xpression was not statistically different from wild-type mice at 7 days, the mRNA levels peaked at 14 days and remained elevated at 21 days relative to wild type and RGC *Panx1*^−*/*−^ mice (*P* \< 0.0005). Retinal sections were further evaluated by immunolabeling, which showed an increase in GFAP expression in the nerve fiber layer and through the retinal layers, consistent with astrocyte and Müller cell activation (Fig. [12](#Fig12){ref-type="fig"}). The increase in GFAP was present in all genotypes, and at all post-crush time points examined, while the control eyes only exhibited baseline levels of GFAP by astrocytes. GFAP labeling appeared to be most prominent at 7 and 14 days, although Müller cell activation was still prevalent by 21 days.Fig. 11Genetic ablation of *Panx1* from RGCs does not reduce macroglial activation after optic nerve crush. We hypothesized that PANX1 hemichannels mediated ATP release from dying RGCs, and we examined the role of this protein in the crush paradigm by using mice genetically deficient for *Panx1* in either RGCs or all cell types. **a** QPCR analysis showed that, relative to wild-type mice, total knockout mice expressed undetectable levels of *Panx1*, while RGC conditional knockout mice exhibited a 50 % reduction in mRNA expression. **b** Wild-type and *Panx1*-deficient mice were then subjected to crush and analyzed for macroglial activation. Wild-type mice exhibited characteristic *Gfap* expression, with levels peaking at 7 days before declining at 14 and 21 days. Similarly, at 7 days in the *Panx1* ^−/−^ mice, *Gfap* mRNA abundance was highest, and gradually declined at 14 and 21 days. Mice deficient for *Panx1* in RGCs exhibited sustained levels of macroglial activation as *Gfap* expression rose between 7 and 14 days, and remained significantly elevated above wild-type mice at 21 days post-crush. Data is presented as mean ± SD. \**P* \< 0.0005, \*\**P* \< 0.0001. For each genotype at each time point, *n* ≥ 3Fig. 12Müller cell upregulation of GFAP after optic nerve crush is not affected by *Panx1* deficiency. Wild-type and *Panx1* conditional knockout mice were evaluated for GFAP expression after optic nerve crush. Genetic ablation of *Panx1* did not appear to alter astrocyte expression of GFAP in control eyes (**a**, **e**, **i**). At 7, 14, and 21 days post-crush, all genotypes exhibited a clear upregulation of GFAP, indicated by an increase in intensity in the nerve fiber layer, and through the retinal layers, consistent with Müller cell activation. GFAP expression appeared strongest between 7 and 14 days, although Müller cell expression of GFAP was still present 21 days after crush injury. There did not appear to be an obvious difference in the pattern of macroglial activation between the three genotypes. *Scale bar* 50 μm. For wild-type and *Panx1* ^*−*/*−*^ mice, at each time point *n* ≥ 3. For *Panx1* ^*−*/*−*^ RGC mice, 7 days *n* = 3, and at 14 and 21 days *n* = 2

Discussion {#Sec15}
==========

The timing of RGC pathology and glial activation after optic nerve damage {#Sec16}
-------------------------------------------------------------------------

An understanding of the sequence of events being executed in damaged RGCs is relevant to understanding how retinal glia respond. We have monitored the glial response using the markers *Aif1* and *Gfap*. We previously determined that mRNA levels for these markers become elevated between 3 and 5 days after crush \[[@CR55]\]. Importantly, both glial populations appeared to be synchronized with RGC pathology that followed the interval of BAX protein activation, which is estimated to occur by 3 days after acute optic nerve damage \[[@CR91], [@CR92]\] (M. Maes and R. Nickells, unpublished data), suggesting that apoptotic events downstream of the BAX-dependent step were linked to the signaling mechanism leading to the glial response. This, in fact, appears to be the case, since both microglial and macroglial responses are significantly suppressed in the absence of RGC death in *Bax*-deficient mice. A caveat in our study is that microglial and macroglial activation rose modestly in the injured and contralateral retinas of both genotypes. Additional activation signals, while minimally influential, may be released prior to the *Bax*-dependent step of the apoptotic program, or originate from a source other than dying RGCs.

Potential role of purinergic signaling between injured RGCs and retinal glia {#Sec17}
----------------------------------------------------------------------------

Given the prerequisite for RGC death and the timing of the glial response, we reasoned that RGCs could be communicating with the glia via purinergic signaling pathways. We show that an injection of BzATP into the mouse eye stimulates *Gfap* expression in retinal macroglia, including Müller cells. This is particularly intriguing, since BzATP is historically considered a specific agonist for the P2X7 receptor \[[@CR93]\], and there is conflicting evidence about the expression of this receptor by Müller cells \[[@CR94]--[@CR96]\]. How then, do the Müller glia respond to BzATP? It is possible that different purinergic receptors on Müller cells are responding to the agonist, especially at the relatively high concentrations that were used for intravitreal injection. BzATP is a similarly potent agonist for the P2X1 receptor, and has partial activity for multiple P2X and P2Y1 receptors \[[@CR97]--[@CR99]\]. While there is evidence that P2X7R is not expressed by mammalian Müller cells, there are reports that Müller cells in the lower vertebrate species do express this receptor \[[@CR96]\]. Additionally, we cannot rule out that this receptor is not upregulated in Müller cells under stress conditions \[[@CR100]\]. Lastly, it may be possible that the Müller cell response was secondary to the action of BzATP on either RGCs or astrocytes, which do contain P2X7 receptors \[[@CR94], [@CR101]\]. Activation of P2X7R on other cell types may lead to ATP release that then affect the Müller cells via a different purinergic receptor \[[@CR102]\]. Experiments using P2X antagonists shed little light on this mechanism. While we show that oxATP, also considered a relatively selective antagonist for the P2X receptors \[[@CR103]\], can partially suppress the macroglial response, this does not rule out a secondary activating mechanism from the astrocytes or RGCs to the Müller cells. Additionally, suppression of glial activation using oxATP appears to selectively affect the response in astrocytes when assessed by immunostaining. Further studies are necessary to help elucidate the purinergic signaling network in the retina after optic nerve damage.

While purinergic signaling appears to play a role in macroglial activation, our data do not show an effect on microglial activation, at least in the context of upregulating *Aif1* expression. Microglia reportedly express the P2X7 receptor \[[@CR104], [@CR105]\], and activation of this receptor has been directly linked to microglial inflammatory responses in rat primary hippocampal cultures \[[@CR71]\]. Nevertheless, experiments using both BzATP and oxATP appear to exclude purinergic signaling to activate these cells after optic nerve damage, and it is not possible to rule out an effect on the microglia based on other metrics typical of their activation response. It is clear, however, that *Bax*-deficient mice exhibit a suppression of microglial activation in this damage paradigm, which is consistent with a recent study using an acute ethanol toxicity model, in which microglial activation was also suppressed in *Bax*^−/−^ mice \[[@CR106]\]. The signaling pathway linking RGCs and microglia was not a focus of this study, but we hypothesize that it likely occurs via Toll-like receptors (TLRs). This is supported by three lines of experimental evidence. Retinal microglia upregulate TLR expression as an early response to glaucomatous damage \[[@CR107]\], polymorphisms in both *TLR2* and *TLR4* are risk alleles for glaucoma \[[@CR108], [@CR109]\], and deletion of *Tlr4* in mice reduces RGC death after optic nerve damage \[[@CR110]\] and ischemia-reperfusion \[[@CR111]\]. TLRs respond to endogenously derived "damage-associated molecular pattern" (DAMP) molecules released from damaged or dying cells \[[@CR3]\]. For example, TLR9 additionally recognizes mitochondrial DNA \[[@CR112]\], which would only be released from cells undergoing mitochondrial breakdown, a feature expected only in cells with a functional BAX protein. Perhaps, not coincidentally, this receptor has also been linked to glial activation in the retina \[[@CR113]\].

One noteworthy observation in our study involving the microglia response in wild-type mice after optic nerve damage is the increase in ramifications of these cells at 7 days after injury. The classic activation response of microglia is to convert to a more amoeboid state by the retraction of processes, after which they enter a transitional/motile phenotype by extending new processes \[[@CR21]\]. It is possible that our observations at 7 days correspond to cells already in this transitional phase.

PANX1 function in RGCs after optic nerve damage {#Sec18}
-----------------------------------------------

Based on the suppressed glial response in Bax-deficient mice, and the pharmacologic evidence suggesting a role for purinergic signaling in macroglial activation, we hypothesized that ATP was released from dying RGCs via activated PANX1 channels. This hypothesis was particularly attractive given that mechanical stress applied to RGCs elicits ATP release via PANX1 hemichannels \[[@CR65]\]. Additionally, activated caspases proteolytically activate PANX1 \[[@CR60]\]; therefore, PANX1 activation would not occur in *Bax*-deficient cells, which fail to stimulate caspases. However, *Panx1* ablation in RGCs failed to reduce the macroglial response invalidating our hypothesis. Several lines of evidence implicate PANX1 as playing a role in RGC pathology, although none of these studies evaluated the effects after optic nerve damage. In ischemia damage models, deletion of *Panx1* in RGCs provides a protective response \[[@CR78]\], including attenuation of neurotoxic Ca^2+^ uptake. *Panx1*^−/−^ RGCs also exhibited impaired activation of the inflammasome. Tied with this is evidence that prolonged exposure to ATP analogs, including BzATP, stimulates RGC loss \[[@CR75], [@CR76]\], presumably through the interaction of P2X7 receptors and PANX1 \[[@CR114]\] on RGCs. In preliminary experiments, however, we did not detect a similar protective effect for RGCs after optic nerve damage when *Panx1* was selectively deleted in these neurons (data not shown). Conversely, optic nerve crush in the eyes with *Panx1*^−/−^ RGCs resulted in what appeared to be an elevated and sustained macroglial response, measured as a function of *Gfap* expression. This argues for a role of PANX1 channels in paracrine signaling between RGCs and activated macroglia to modulate or shutdown the activation response, although the nature of this paracrine response is yet to be determined.

A major caveat to our observations is that the sustained activation of macroglia after crush was not observed in the complete *Panx1*^−/−^ mouse as well. Currently, we have not been able to reconcile these conflicting results. One possible explanation, however, is the developmental timing of the *Panx1* deletion. In complete (zygotic) knockout mice generated by crossing animals with a floxed *Panx1* allele to the CMV-*Cre* transgenic line, the disabling of *Panx1* alleles occurs as early as the 1-2 cell stage of development \[[@CR115]\]. Under these conditions, it is conceivable that *Panx1*^−/−^ mice develop compensatory mechanisms to overcome the loss of PANX1 hemichannels. Consistent with this, multiple functions attributed to *Panx1* have only been observed in mice with both *Panx1* and *Panx2* deleted \[[@CR116]\]. In contrast, RGC-specific deletion of *Panx1* by AAV2-Cre injection is achieved well into adulthood, thereby excluding the development of a compensatory mechanism in these cells. We posit that these experiments more accurately reflect a role for *Panx1* in these cells.

Glial cell representation and morphology in *Bax*-deficient mice {#Sec19}
----------------------------------------------------------------

We used *Bax*^−/−^ mice to assess the relationship between RGC death and retinal glial activation, principally because RGCs lacking this proapoptotic member of the *Bcl2* gene family exhibit complete and sustained prevention of RGC loss in optic nerve damage paradigms \[[@CR50]--[@CR54]\]. It is relevant, however, to consider how the loss of *Bax* affects the glial population in our interpretation of the results of this study. This is especially important, given the well-documented phenomenon that *Bax*-deficiency leads to supernumerary numbers of some classes of neurons in the mouse \[[@CR117]--[@CR119]\]. Surprisingly, there is very little information regarding glial populations in the CNS of *Bax*-deficient mice. White and colleagues \[[@CR118]\] found no evidence of reduced cell death of glial populations in these mice, presumably because they also express a functional proapoptotic BAK protein, unlike neurons, which alternatively splice the *Bak* transcript \[[@CR120]\]. Conversely, oligodendrocyte cell density in the optic nerves of *Bax*-deficient mice is greater, retaining a normal ratio with the increased axon number \[[@CR121]\]. Our comparison of microglial density in the peripheral retinal nerve fiber layers of wild-type and *Bax*-deficient mice suggests that there is no increase in microglial cells commensurate with the reported increase in RGCs \[[@CR50], [@CR122], [@CR123]\]. The microglial population in the retinas of *Bax*-deficient mice is different from wild-type littermates, however, and appears to be enriched in cells with more amoeboid-like characteristics. The reason for this enrichment is not known, but perhaps *Bax* deficiency provides a bias towards a subclass of microglia \[[@CR124]\] by preventing programmed cell death during development, similar to the phenomenon exhibited by neuronal populations. Importantly, however, our experiments using the excitotoxic agent NMDA to induce RGC death indicate that both microglia and macroglia in *Bax*^−/−^ mice were able to upregulate markers consistent with a normal activation response.

Conclusions {#Sec20}
===========

Glial activation is associated with the neuroinflammatory response of many neurodegenerative conditions, but the signaling pathways eliciting this process are not fully defined. Here, we show that neuronal death appears to be a prerequisite for the full activation response observed in the retina after optic nerve damage, and that this response is modulated by purinergic signaling. This helps explain why *Bax*-deficient RGCs are completely resistant to optic nerve damage, even though the extrinsic apoptotic pathways, which would be activated during neuroinflammation, remain intact in these cells.

Additional file {#Sec21}
===============

Additional file 1: Figure S1.Summary of Sholl analysis of AIF1-expressing microglia after optic nerve crush. (A--C) Wild-type retinas at 7, 14, and 21 days after optic nerve crush, respectively. (D--F) Bax^−/−^ retinas at 7, 14, and 21 days, respectively. Data is presented as mean ± SE. \**P* \< 0.05. Each graph represents a minimum of 50 cells measured from three retinas of each genotype. (JPG 2.19 mb)
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:   allograft inflammatory factor 1

ATP

:   adenosine triphosphate

BzATP

:   2′(3′)-O-(4-benzoylbenzoyl)adenosine 5′-triphosphate triethylammonium salt

CD68

:   cluster of differentiation 68/macrosialin

GFAP

:   glial fibrillary acid protein

NES

:   nestin

NMDA

:   *N*-*methyl*-[d]{.smallcaps}-aspartate

oxATP

:   oxidized ATP

PANX1

:   pannexin 1

RGC

:   retinal ganglion cell
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